UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 373

Sortiert nach

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant

Breast cancer research : BCR, 2023-08, Vol.25 (1), p.1-103, Article 103

2023

Link zum Volltext

Verfügbarkeit prüfen

Quantitative Association Between HER-2/neu and Steroid Hormone Receptors in Hormone Receptor-Positive Primary Breast Cancer

JNCI : Journal of the National Cancer Institute, 2003-01, Vol.95 (2), p.142-153

2003

Link zum Volltext

Verfügbarkeit prüfen

KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition

British journal of cancer, 2014-10, Vol.111 (9), p.1788-1801

2014

Link zum Volltext

Verfügbarkeit prüfen

Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer

JNCI : Journal of the National Cancer Institute, 2004-05, Vol.96 (10), p.739-749

2004

Link zum Volltext

Verfügbarkeit prüfen

Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer

JNCI : Journal of the National Cancer Institute, 2004-05, Vol.96 (10), p.759-769

2004

Link zum Volltext

Verfügbarkeit prüfen

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells

British journal of cancer, 2009-11, Vol.101 (10), p.1699-1708

2009

Link zum Volltext

Verfügbarkeit prüfen

Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy

Annals of oncology, 2005-11, Vol.16 (11), p.1772-1777

2005

Link zum Volltext

Verfügbarkeit prüfen

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

The New England journal of medicine, 2018-11, Vol.379 (20), p.1926-1936

2018

Link zum Volltext

Verfügbarkeit prüfen

Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1

Annals of oncology, 2006-04, Vol.17 (4), p.597-604

2006

Link zum Volltext

Verfügbarkeit prüfen

Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

Annals of oncology, 2021-08, Vol.32 (8), p.1015-1024

2021

Link zum Volltext

Verfügbarkeit prüfen

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

Journal of clinical oncology, 1999-09, Vol.17 (9), p.2639-2648

1999

Link zum Volltext

Verfügbarkeit prüfen

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells

British journal of cancer, 2008-03, Vol.98 (6), p.1076-1084

2008

Link zum Volltext

Verfügbarkeit prüfen

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

Breast cancer research and treatment, 2019-04, Vol.174 (3), p.719-729

2019

Link zum Volltext

Verfügbarkeit prüfen

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial

Annals of oncology, 2018-04, Vol.29 (4), p.888-894

2018

Link zum Volltext

Verfügbarkeit prüfen

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

Journal of clinical oncology, 1997-08, Vol.15 (8), p.2894-2904

1997

Link zum Volltext

Verfügbarkeit prüfen

Combination therapy with Trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer : Evidence for receptor-enhanced chemosensitivity

Seminars in oncology, 1999-08, Vol.26 (4), p.89-95

1999

Link zum Volltext

Verfügbarkeit prüfen

Prognostic classification of breast ductal carcinoma-in-situ

The Lancet (British edition), 1995-05, Vol.345 (8958), p.1154-1157

1995

Link zum Volltext

Verfügbarkeit prüfen

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

Oncogene, 1998-10, Vol.17 (17), p.2235-2249

1998

Link zum Volltext

Verfügbarkeit prüfen

Frozen Tumor Tissue Microarray Technology for Analysis of Tumor RNA, DNA, and Proteins

The American journal of pathology, 2001-11, Vol.159 (5), p.1645-1650

2001

Link zum Volltext

Verfügbarkeit prüfen

FOXA1 represses the molecular phenotype of basal breast cancer cells

Oncogene, 2013-01, Vol.32 (5), p.554-563

2013

Link zum Volltext

Verfügbarkeit prüfen

Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas

Nature genetics, 1999-02, Vol.21 (2), p.236-240

1999

Link zum Volltext

Verfügbarkeit prüfen

Trastuzumab and chemotherapeutics : Drug interactions and synergies

Seminars in oncology, 2000-12, Vol.27 (6), p.21-25

2000

Link zum Volltext

Verfügbarkeit prüfen

Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer

Gynecologic oncology, 2023-03, Vol.170, p.221-228

2023

Link zum Volltext

Verfügbarkeit prüfen

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

Oncogene, 1997-07, Vol.15 (5), p.537-547

1997

Link zum Volltext

Verfügbarkeit prüfen

Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells

Oncogene, 1994-07, Vol.9 (7), p.1829-1838

1994

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 373

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(368)
Mit Volltextzugriff
(337)

Publikationsform

Artikel
(370)
Tagungsberichte
(3)

Sprache

Englisch
(372)
Japanisch
(47)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant

Quantitative Association Between HER-2/neu and Steroid Hormone Receptors in Hormone Receptor-Positive Primary Breast Cancer

KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition

Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer

Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells

Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1

Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

Combination therapy with Trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer : Evidence for receptor-enhanced chemosensitivity

Prognostic classification of breast ductal carcinoma-in-situ

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

Frozen Tumor Tissue Microarray Technology for Analysis of Tumor RNA, DNA, and Proteins

FOXA1 represses the molecular phenotype of basal breast cancer cells

Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas

Trastuzumab and chemotherapeutics : Drug interactions and synergies

Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells

Suchergebnisse filtern